



IND 59,408

Allergan, Inc.  
Attention: Elizabeth Bancroft  
Senior Director, Regulatory Affairs  
2525 Dupont Drive  
P.O. Box 19534  
Irvine, California 92623-9534

Dear Ms. Bancroft:

To obtain needed pediatric information on gatifloxacin for the treatment of bacterial conjunctivitis, the Food and Drug Administration (FDA) is hereby making a formal Written Request, pursuant to Section 505A of the Federal Food, Drug, and Cosmetic Act, that information be submitted from the following study:

**Type of Study:**

The study should be a randomized, double-masked, parallel comparison trial. The study should be of at least 1 week duration and should include a minimum of three evaluations, for example, baseline, day 3±1 day, and end of treatment.

**Indication/Objective:**

The primary objective of the study should be to evaluate the safety and the clinical improvement rate between treatment groups. Enrolled patients should include male and female pediatric patients with a clinical diagnosis of presumed bacterial conjunctivitis.

**Study Endpoints:**

The primary endpoint should be clearing of the infection based on an external ophthalmologic examination. Additionally, conjunctival cultures must be taken between 2 and 10 days after the start of treatment.

**Age Groups**

Patients should be between the ages of 0 and 1 month. At least 100 culture positive patients or 200 patients with red eyes should be enrolled in the trial.

**Drug Information:**

Gatifloxacin, in an appropriate formulation, should be compared to a concurrent control.

**Labeling:**

Appropriate sections of the label may be changed to incorporate the findings of the study.

**Format of Report To Be Submitted:**

A full study report, not previously submitted to the Agency and addressing the issues outlined in this request, should be provided with a full analysis, assessment, and interpretation.

**Timeframe:**

The report of the above study must be submitted to the Agency on or before January 1, 2004. Please keep in mind that pediatric exclusivity only extends existing patent protection or exclusivity that has not expired or been previously extended at the time you submit your report of the study in response to this Written Request.

Please submit the protocol for the above study to an investigational new drug application (IND) and clearly mark your submission “**PEDIATRIC PROTOCOL SUBMITTED FOR PEDIATRIC EXCLUSIVITY STUDY**” in large font, bolded type at the beginning of the cover letter of the submission. Please notify us as soon as possible if you wish to enter into a written agreement by submitting a proposed written agreement. Clearly mark your submission “**PROPOSED WRITTEN AGREEMENT FOR PEDIATRIC STUDIES**” in large font, bolded type at the beginning of the cover letter of the submission.

The report of this study should be submitted as a new NDA or as a supplement to an approved NDA, with the proposed labeling changes you believe would be warranted based on the data derived from this study. When submitting the report, please clearly mark your submission “**SUBMISSION OF PEDIATRIC STUDY REPORTS-PEDIATRIC EXCLUSIVITY DETERMINATION REQUESTED**” in large font, bolded type at the beginning of the cover letter of the submission and include a copy of this letter. Please also send a copy of the cover letter of your submission, via fax (301-594-0183) or overnight mail/messenger to the Director, Office of Generic Drugs, HFD-600, Metro Park North II, 7500 Standish Place, Rockville, Maryland 20855-2773.

If you wish to discuss any amendments to this Written Request, please submit proposed changes and the reasons for the proposed changes to your application. Submissions of proposed changes to this request should be clearly marked “**PROPOSED CHANGES IN WRITTEN REQUEST FOR PEDIATRIC STUDIES**” in large font, bolded type at the beginning of the cover letter of the submission. You will be notified in writing if any changes to this Written Request are agreed upon by the Agency.

We hope you will fulfill this pediatric study request. We look forward to working with you on this matter in order to develop additional pediatric information that may produce health benefits for the pediatric population.

IND 59,408

Page 3

If you have any questions, call Lori M. Gorski, Project Manager, at (301) 827-2090.

Sincerely,

*{See appended electronic signature page}*

Jonca C. Bull, M.D.

Acting Director

Office of Drug Evaluation V

Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Jonca Bull  
10/4/01 10:22:52 AM